Table 1.
Patient characteristics in the pre-COVID and COVID cohorts
| Pre-COVID cohort (n = 162) | COVID cohort (n = 53) | P value | |
|---|---|---|---|
| Recipient age, mean ± SD | 45.5 ±14.1 | 47.6 ±11.6 | 0.3 |
| Gender, males, n (%) | 130 (80.2) | 45 (84.9) | 0.5 |
| MELD score, median (IQR) | 18 (12.7-24) | 16 (10.5-19.5) | 0.2 |
| MELD groups, n (%) | 0.1 | ||
| ≤10 | 19 (11.8) | 11 (20.7) | |
| 11-19 | 76 (46.9) | 29 (54.7) | |
| 20-29 | 53 (32.7) | 10 (18.9) | |
| ≥30 | 14 (8.6) | 3 (5.7) | |
| MELD > 20 | 67 (41.3) | 13 (24.5) | 0.03 |
| Etiology, n (%) | 0.7 | ||
| HCV infection | 66 (40.7) | 28 (52.8) | |
| HBV infection | 23 (14.2) | 9 (17) | |
| HBV and HDV infection | 25 (15.4) | 9 (17) | |
| Cryptogenic | 34 (21) | 6 (11.3) | |
| Others | 14 (8.6) | 1 (1.9) | |
| Hepatocellular carcinoma, n (%) | 57 (35.1) | 20 (37.7) | 0.7 |
| Portal vein thrombosis, n (%) | 26 (16) | 8 (15.1) | 0.8 |